TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT

TRIB2 as a biomarker for diagnosis and progression of melanoma

(2015) Richard Hill et al.   CARCINOGENESIS

Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy

(2015) Helena Cirenajwis et al.   Oncotarget

Targeting PI3K/Akt/mTOR Signaling in Cancer

(2014) Camillo Porta et al.   Frontiers in Oncology

Stalling the Engine of Resistance: Targeting Cancer Metabolism to Overcome Therapeutic Resistance

(2013) E. B. Butler et al.   CANCER RESEARCH

Identification of Tribbles-1 as a Novel Binding Partner of Foxp3 in Regulatory T Cells

(2013) Emilie Dugast et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Tribbles in disease: Signaling pathways important for cellular function and neoplastic transformation

(2011) Takashi Yokoyama et al.   CANCER SCIENCE

Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding

(2010) K. Keeshan et al.   BLOOD

Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells

(2010) F Zanella et al.   ONCOGENE

Analysis of innate immune signal transduction with autocatalytic expression vectors

(2008) Hongtao Guan et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Analyzing real-time PCR data by the comparative CT method

(2008) Thomas D Schmittgen et al.   Nature Protocols